Atlanta, GEORGIA24 Active Studies

Atopic Dermatitis Clinical Trials in Atlanta, GEORGIA

Find 24 actively recruiting atopic dermatitis clinical trials in Atlanta, GEORGIA. Connect with local research sites and explore new treatment options.

24
Active Trials
22
Sponsors
5,058
Enrolling

Recruiting Atopic Dermatitis Studies in Atlanta

RecruitingAtlanta, GEORGIANCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

787 participants
Eli Lilly and Company
View Study Details
RecruitingAtlanta, GEORGIANCT04892173

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab ...

500 participants
Johnson & Johnson Enterprise Innovation Inc.
View Study Details
RecruitingAtlanta, GEORGIANCT06510374

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)...

454 participants
Ferring Pharmaceuticals
View Study Details
RecruitingAtlanta, GEORGIANCT06064877

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and ...

410 participants
AVEO Pharmaceuticals, Inc.
View Study Details
RecruitingAtlanta, GEORGIANCT04534205

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unres...

350 participants
BioNTech SE
View Study Details
RecruitingAtlanta, GEORGIANCT05721755

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patien...

290 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingAtlanta, GEORGIANCT06545955

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...

250 participants
Ferring Pharmaceuticals
View Study Details
RecruitingAtlanta, GEORGIANCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD)....

224 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAtlanta, GEORGIANCT04915183

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of...

224 participants
National Institute on Deafness and Other Communication Disorders (NIDCD)
View Study Details
RecruitingAtlanta, GEORGIANCT06685835

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

The primary purpose of the study is evaluate the effect of brensocatib compared with placebo....

204 participants
Insmed Incorporated
View Study Details
RecruitingAtlanta, GEORGIANCT06863961

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD)....

160 participants
Hoffmann-La Roche
View Study Details
RecruitingAtlanta, GEORGIANCT06215144

Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD

To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD...

160 participants
Neurocentria, Inc.
View Study Details
RecruitingAtlanta, GEORGIANCT06055439

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

135 participants
Chimeric Therapeutics
View Study Details
RecruitingAtlanta, GEORGIANCT06366464

A Study of Pitolisant in Patients With Prader-Willi Syndrome

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The ...

134 participants
Harmony Biosciences Management, Inc.
View Study Details
RecruitingAtlanta, GEORGIANCT05651022

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tisl...

120 participants
Indaptus Therapeutics, Inc
View Study Details
RecruitingAtlanta, GEORGIANCT06144645

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS....

102 participants
Foundation for Prader-Willi Research
View Study Details
RecruitingAtlanta, GEORGIANCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingAtlanta, GEORGIANCT06049680

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipi...

100 participants
Fresenius Kabi
View Study Details
RecruitingAtlanta, GEORGIANCT06828861

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingAtlanta, GEORGIANCT07197034

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us ...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingAtlanta, GEORGIANCT05814666

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of pati...

81 participants
Flamingo Therapeutics NV
View Study Details
RecruitingAtlanta, GEORGIANCT06798012

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...

36 participants
Takeda
View Study Details
RecruitingAtlanta, GEORGIANCT05487170

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous ...

32 participants
Ranok Therapeutics (Hangzhou) Co., Ltd.
View Study Details
RecruitingAtlanta, GEORGIANCT05756569

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that h...

25 participants
Emory University
View Study Details

About Atopic Dermatitis Clinical Trials in Atlanta

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 24 atopic dermatitis clinical trials recruiting participants in Atlanta, GEORGIA. These studies are seeking a combined 5,058 participants. Research is being sponsored by Eli Lilly and Company, Johnson & Johnson Enterprise Innovation Inc., Ferring Pharmaceuticals and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Atlanta — FAQ

Are there atopic dermatitis clinical trials in Atlanta?

Yes, there are 24 atopic dermatitis clinical trials currently recruiting in Atlanta, GEORGIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Atlanta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.

Are clinical trials in Atlanta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 24 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov